Bio Pharma Dive
APRIL 25, 2025
The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.
ACRP blog
APRIL 25, 2025
At the latest meeting of the Association of Clinical Research Professionals (ACRP)-led Partners Advancing the Clinical Research Workforce (PACRW) consortium, the focus for these extraordinary times in human subjects research was on what levers need to be pulled by the consortiums members to bend the curve toward a better future for stakeholders in what is often an under-recognized and under-resourced segment of the larger healthcare workforce.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
APRIL 25, 2025
Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final resolution.
Bio Pharma Dive
APRIL 25, 2025
The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance trainings aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, relevant, and maybe even enjoyable! Join expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training programs. You’ll discover creative strategies to turn traditionally dry topics into meaningful learning experiences that resonate and drive real change.
XTalks
APRIL 25, 2025
This week, LEO Pharma announced the publication of pivotal Phase III clinical trial results in The Lancet for its topical delgocitinib cream to treat severe chronic hand eczema (CHE). Results from the trial showed delgocitinib to have superior efficacy and safety over oral alitretinoin, the current standard of care for CHE. The DELTA FORCE trial is the first head-to-head Phase III study comparing a topical treatment with a systemic therapy for CHE.
Bio Pharma Dive
APRIL 25, 2025
The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for Trodelvy and its cancer cell therapies.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Bio Pharma Dive
APRIL 25, 2025
Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an FDA rejection dragged on, while Sanofi revealed an immune drug setback.
Pharmaceutical Technology
APRIL 25, 2025
Granite Bio has secured $100m in funding for its new antibody treatments that target several autoimmune diseases.
Medical Xpress
APRIL 25, 2025
It's no secret that our waistlines often expand in middle age, but the problem isn't strictly cosmetic. Belly fat accelerates aging and slows down metabolism, increasing our risk for developing diabetes, heart problems and other chronic diseases. Exactly how age transforms a six pack into a softer stomach, however, is murky.
Pharmaceutical Technology
APRIL 25, 2025
Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Pharma Times
APRIL 25, 2025
MHRA authorises drug for adults with rare heart muscle damage
Pharmaceutical Technology
APRIL 25, 2025
The EC has granted orphan drug designation to Dyne Therapeutics DYNE-251 for treating Duchenne muscular dystrophy (DMD).
pharmaphorum
APRIL 25, 2025
Ozempic patient blinded by NAION sues Novo Nordisk Jonah.
Pharma Times
APRIL 25, 2025
Cambridge firm in-licenses two oncology programmes
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
pharmaphorum
APRIL 25, 2025
Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.
Medical Xpress
APRIL 25, 2025
Our lives are filled with binary decisionschoices between one of two alternatives. But what's really happening inside our brains when we engage in this kind of decision making?
pharmaphorum
APRIL 25, 2025
Merck KGaA has confirmed that talks to buy SpringWorks have advanced to the 'late-stage' and are revolving around an offer of around $47 per share
Medical Xpress
APRIL 25, 2025
Patients with spastic paraplegia type 15 develop movement disorders during adolescence that may ultimately require the use of a wheelchair. In the early stages of this rare hereditary disease, the brain appears to play a major role by over-activating the immune system, as shown by a recent study published in the Journal of Experimental Medicine.
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
Pharmaceutical Commerce
APRIL 25, 2025
Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.
Medical Xpress
APRIL 25, 2025
New data published in The Journal of Immunology has revealed the role of Plasmodium falciparum infection (malaria) in the development of Burkitt lymphoma (BL), the most common childhood cancer in equatorial Africa and New Guinea. BL has been associated with P. falciparum malaria since 1958, but the underlying mechanism of how it led to cancer had remained a mystery.
pharmaphorum
APRIL 25, 2025
AbbVie is hoping to extend its range of neurotoxin-based pharma and cosmetic products with a short-acting successor to its blockbuster Botox brand.
Medical Xpress
APRIL 25, 2025
Novavax's COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company said Wednesday.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
pharmaphorum
APRIL 25, 2025
Our round-up of recent biotech financings includes rounds for Granite Bio, Biolinq, Etiome, Grove Biopharma, and Synthetic Design Lab
Medical Xpress
APRIL 25, 2025
Six in 10 women believe they will hit menopause in their 40s, according to survey results released April 8 by The Ohio State University Wexner Medical Center in Columbus.
pharmaphorum
APRIL 25, 2025
Leela Barham takes stock of the debate surrounding the UKs current pricing and access deal that caps NHS spend on branded medicines, after a higher-than-expected payback rate for 2025.
Pharmaceutical Commerce
APRIL 25, 2025
In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, explains what the mindset be for companies who are just starting the reshoring process.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
APRIL 25, 2025
Today digital innovationsmost notably electronic clinical outcome assessments (eCOAs)are reshaping clinical trial methodologies, particularly in the rare disease space.
Medical Xpress
APRIL 25, 2025
Differentiated thyroid cancer patients who receive radioiodine (RAI) treatment after surgery have increased relative survival rates compared to those who do not receive the treatment. According to new research published in the April issue of The Journal of Nuclear Medicine, the clear trend for a higher long-term survival rate is observed in subgroups of patients with low- and intermediate-risk disease, while there is special benefit in high-risk diseases.
Pharmaceutical Technology
APRIL 25, 2025
The FDA has granted approval to Akeso's differentiated programmed cell death protein 1 (PD-1) monoclonal antibody, penpulimab-kcqx,
Medical Xpress
APRIL 25, 2025
Take a stroll down the middle aisles of any American grocery store, and you'll be surrounded by rows of brightly colored packaged macaroni and cheese, instant soups and chips in all forms and flavorsall with long ingredient lists. These and other familiar favorites offer consumers a convenient, tasty and often affordable meal or snack.
Expert insights. Personalized for you.
272 
Let's personalize your content